Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Hypertension, Primary, 2 Clear all
Completed Phase 2 Interventional

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

NCT01265888
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Selonsertib in Adults With Pulmonary Arterial Hypertension

NCT02234141
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Selonsertib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 3 Interventional

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

NCT00091598
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT03496207
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Sotatercept, SOC
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

NCT05975905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
Biological
Lead sponsor
Keros Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Beta-blockers in Pulmonary Arterial Hypertension

NCT02507011
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04456998
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

NCT01725269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension Biorepository and Registry

NCT04808596
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

NCT02736149
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • La Jolla, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 21, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

NCT07318597
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
REGN13335, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

NCT04732221
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Interventions
Frespaciguat, Placebo to Frespaciguat
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01725256
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001 (sodium nitrite inhalation solution)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

NCT04712669
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 21, 2026, 11:27 AM EDT
Withdrawn Phase 1 Interventional

A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension

NCT02684786
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
reserpine, stellate ganglion block, lidocaine
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

NCT06664801
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Background PAH Therapy
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

NCT00832507
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Cicletanine, Cicletanine Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 21, 2026, 11:27 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

NCT01457781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 21, 2026, 11:27 AM EDT
Active, not recruiting Phase 2 Interventional

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

NCT01179334
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 21, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 11:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 21, 2026, 11:27 AM EDT